- Power hour: getting you up to speed at speed! 5 short presentations on important breast updates for 2021/2022
- Greater depth sessions focusing on:
- Early diagnosis and screening
- Research and trials
- Improving patient pathways
- Secondary breast cancer
- Breakout sessions aimed at different roles with the breast MDT
Suitable for all members of the breast multidisciplinary team including doctors, specialist nurses, allied health professionals, and researchers.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than 3 decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
With a portfolio spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. Its portfolio includes several global brands and franchises, such as Pierre Fabre Dermatologie and Pierre Fabre Oncologie.
Pierre Fabre is committed to delivering treatment options to patients with cancer and has been working with oncologists for 30 years to make a difference in their clinical practice.
Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation. Pierre Fabre Limited is the UK subsidiary of Pierre Fabre.
Pierre Fabre has funded the educational/scientific content of this meeting only. It has not been involved with or influenced the content, agenda or speaker selection.
Sign up to our education events mailing list to be kept up to date with this and future events